New combo therapy aims to boost immune system against ovarian cancer
NCT ID NCT02726997
Summary
This study is testing whether adding an immunotherapy drug called durvalumab to standard chemotherapy is safe and effective for treating advanced ovarian, fallopian tube, or primary peritoneal cancer. It involves 18 patients who have not had prior treatment. The goal is to see if the drug combination helps the body's immune system better attack the cancer and control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III OVARIAN CANCER AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.